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Human leukocyte interferon was injected into nine patients with cytomegalovirus
infections; four of these patients were congenitally infected, and five had ac-
quired infections. In three patients viruria was completely inhibited. In five pa-
tients viral excretion in the urine was only transiently inhibited. Viremia was not
significantly suppressed. The lymphocyte response to phytohemagglutinin was
suppressed in two patients.
Cytomegalovirus (CMV) has been associated with
long-term, chronic infections in humans and causes
the most common type of congenital infection.
CMV has the ability to cross the placenta and to
produce chronic infection in the fetus; such infec-
tion leads to serious pathologic changes or death.
About 1.5% of all newborns excreting CMV in
the urine after birth in one study [1] and approx-
imately 3.3 % of viruric newborns in other
studies [2, 3] have had the classical signs of con-
genital CMV infection. Disseminated infection
with CMV occurs in adults who have malignancies
or who are taking corticosteroids [4], in children
with leukemia [5, 6] or lymphosarcoma [7], and
in patients who have had renal or bone-marrow
transplantation [8, 9].
There is no established treatment for congenital
or disseminated infection with cytomegalovirus.
Only a few studies employing adequate virological
monitoring of antiviral chemotherapy have been
reported, and these studies revealed variable re-
sults in a small number of patients. FIuorodeoxy-
uridine, iododeoxyuridine, or cytosine arabinoside
did not significantly alter the clinical course of
illness or viral excretion [10-12].
Evidence exists that interferon may be one de-
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terminant of host resistance to viral infections
[13-15]. In a nonrandomized study we have ob-
served a possible antiviral effect of exogenous
human leukocyte interferon in the treatment of
local and generalized infections with herpes sim-
plex virus and varicella-zoster virus [15, 16]. Fal-
coff has reported a beneficial effect of exogenous
amniotic interferon in the treatment of congenital
CMV infection [17]. Our study was initiated to
examine the effect of human leukocyte interferon
on the rate of excretion of CMV in the urine and
in fractions of the buffy coat of patients who are
chronic carriers of CMV.
Materials and Methods
Human leukocyte interferon was prepared in our
laboratory. Details regarding production, purifica-
tion, standardization, and sterilization of this prep-
aration have been described previously [15]. In-
terferon levels in administered preparations were
assayed by microtitration techniques; vesicular
stomatitis virus was inhibited in human foreskin
fibroblast monolayers [18].
Isolations of virus from urine, leukocytes, and
lymphocytes were based on growth and cytopatho-
logical characteristics. Clean urine was collected
daily for a period of at least 20 days and processed
immediately. Each of five tubes of confluent cul-
tures of WI-38 human fibroblasts in Eagle's min-
imal essential medium (MEM) containing 2% in-
activated fetal calf serum was inoculated with 0.4
ml of MiIIipore-filtered urine at different dilutions.
Tubes containing monolayers that demonstrated
CPE were subcultured, and CMV was identified
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by specific CPE in WI-38 cell cultures, presence
of intranuclear inclusion bodies, lack of CPE in
mouse L-cell cultures, and immunofluorescence
[19]. For studies of antibody, CF tests were done
by a micromethod [20].
Purified lymphocytes were obtained as previ-
ously described [21]. The leukocytes were pre-
pared in the following manner. Heparinized blood
(10 ml) was allowed to sediment at 37 C for
1-1.5 hr. Plasma rich in white blood cells (WBC)
was collected and centrifuged at 300 g for 10 min.
The cells were washed three times in Hanks' bal-
anced salt solution, resuspended in MEM with
2% fetal calf serum, and inoculated into WI-38
cells.
Lymphocyte responses to phytohemagglutinin
(PHA) were tested in microculture [22]; the
thymus-derived (T- )lymphocyte subpopulation
was detected by the spontaneous rosettes that were
formed with sheep erythrocytes. Surface immuno-
globulins were tested according to the methods of
Siegel et al. [23].
Results
Case reports. Patient no. 1 was aone-and-
one-half-year-old boy with congenital CMV infec-
tion (figure 1); he had had frequently recurring
attacks of bronchial pneumonia and viral excre-
tion since birth. His CF antibody titer was 1:60.
Before treatment with human leukocyte interferon,
he had a chronic cough with fever. Human leu-
kocyte interferon was injected im in a single daily
dose of 106 units for 10 days. Before administra-
tion of interferon, all urine samples tested con-
tained CMV. However, three days after com-
mencement of treatment, no virus was detectable
in the urine. Results of urine cultures were still
negative six months after completion of treatment.
Patient no. 2 was a premature infant who had
congenital CMV infection and hepatomegaly with
minimal cerebral dysfunction (figure 1). Before
treatment with human leukocyte interferon, all
results of urine cultures tested for CMV were
positive. The titer of virus was about 102-103
TCIDfjo/OA ml of urine. A few leukocyte cultures
were tested, and CMV was isolated from two of
these cultures. The CF antibody titer of this pa-
tient was 1: 60.
The patient was treated for eight days with a
single daily dose of 5 X 105 units of human leu-
kocyte interferon. No CMV was detectable in the
urine after the fourth day of treatment. Results of
subsequent urine cultures on days 30, 62, 68, and
92 were negative. We were not able to isolate
CMV from the only leukocyte culture tested.
Patient no. 3, a newborn weighing 2,000 g, had
congenital CMV infection and hepatospleno-
megaly with severe thrombopenia (figure 2). Dur-
ing the first month of life, this patient had rectal
bleeding and a thrombocyte count of 15,000/mm3•
Before treatment with human leukocyte interferon,
the patient's urine always contained 102-103
TC1D50 of CMVlOA ml of urine. Even purified
lymphocyte fractions and leukocytes were positive
for the virus. Human leukocyte interferon in single
daily im doses of 106 units was administered to
attain a fairly high level of serum interferon with
a duration of about 8 hr. Interferon was admin-
istered for 10 days. On day 4 of treatment, the pa-
tient's urine was free of virus. However, the in-
hibition was transient. Results of urine cultures
were again positive on the 15th day after the
start of interferon administration and continued to
Figure 1. Excretion of cytomega-
lovirus (CMV) in the urine of pa-
tients no. 1 and no. 2 before, dur-
ing, and after treatment with human
leukocyte interferon. Patient no. 1
received 106 units of interferon
daily, and patient no. 2 received
5 X 105 units daily.
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be positive until treatment was resumed on the
same schedule and in the same dosage as used
previously. Results of blood cultures were nega-
tive after the first course of treatment. The second
course of treatment produced the same transient
inhibition of virus in the urine as the first.
In this patient lymphocyte response to PHA
was measured before, during, and after treatment.
The PHA response was markedly suppressed as
early as the second day of treatment. Five days
after the last injection of interferon (first course),
the PHA response returned, and, 22 days after the
last injection, the PHA-stimulated cultures showed
the same response as before administration, a
finding that indicated normal T-cell function.
Patient no. 4 (figure 3) was a premature infant
with a severe congenital CMV infection accom-
panied by cerebral dysfunction, motor retardation,
hepatomegaly, and splenomegaly. During the first
three months of life, he developed pneumonia.
He continuously excreted a high titer of CMV in
his urine. However, samples of buffy coat and
plasma and lymphocyte cultures yielded no
evidence of CMV. Lymphocyte cultures stimulated
for interferon production showed a deficient pro-
duction of circulating interferon. The patient's
titer of CF antibody to CMV was 1:60.
This patient was treated for 10 days during
three different periods with 2.5 X 105 units of
human leukocyte interferon injected im once daily.
Before the first treatment, all cultures of this pa-
tient's urine revealed> 102 TCID50 of CMV/0.4 ml
of urine. Tests of daily urine cultures during treat-
ment showed a possible transient reduction of
viral excretion in the urine only in the first culture.
This reduction was only marginal, from 102 to 101
TCID50' In the two later courses of treatment, no
antiviral effect was observed, and the urine cul-
tures had a constant titer of virus during the study.
Patient no. 5 was a 27-year-old kidney trans-
plant recipient who had received intensive im-
munosuppressive therapy and had experienced
incipient rejection. The whole clinical course, with
interstitial pneumonia, ascites, and increased rate
of creatine clearance with rejection, was rapid.
At the start of therapy with human leukocyte
interferon, CPE was not detectable in the urine,
blood, or peritoneal fluid. The only indication of
CMV infection was a high titer (1: 120) of CF
antibody. Nevertheless, treatment with human leu-
kocyte interferon was initiated in an im dose of
106 units twice daily. The patient died on day 8
of treatment.
Results of all cultures taken before treatment,
including urine, leukocytes, and macrophages
isolated from the peritoneal fluid, were positive
for CMV. CPE in the WI-38 cell culture was first
observed after 25 days. A possible antiviral effect
was observed in urine cultures after treatment for
five days. In the last three days of treatment, urine
cultures were negative for CMV, whereas leu-
kocytes and macrophages isolated from the ascites
had not been affected by the administration of
interferon. An autopsy revealed typical CMV
inclusion bodies in the kidney.
Patient no. 6, a 40-year-old man with an un-
usual type of CMV hepatitis, developed a gen-
eralized epidermolysis eight weeks after hepatitis
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Figure 3. Excretion of cytomega-
lovirus (CMV) in the urine of pa-
tient no. 4 before, during, and after
treatment with human leukocyte in-
terferon (three courses; 2.5 X 105
units daily).
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had been detected. Details of this case have been
reported elsewhere [24]. During the hepatitis
phase, he excreted virus in the urine, and leuko-
cyte cultures also yielded CMV. After 10 days of
treatment with human leukocyte interferon (10 6
units daily, im), viral excretion in the urine was
completely inhibited. No virus was isolated in 14
consecutive cultures during epidermolysis; how-
ever, CMV was isolated from the lymphocyte
fraction.
Patient no. 7 was treated for herpes zoster with
human leukocyte interferon. He had already de-
veloped an unproductive cough and increasing
dyspnea when therapy was begun. CMV was iso-
lated on the second day of treatment from his
urine. He was treated im twice daily for 10 days
with 106 units of human leukocyte interferon.
After six days viral excretion was inhibited, but
only transiently. Urine cultures yielded CMV
on days 15-18 and day 20 after initiation of
treatment.
Two additional patients have been described
previously.' Patient no. 8 was a six-month-old
male with the adenosine deaminase deficiency
form of severe combined immunodeficiency; he
had had a bone-marrow transplantation. During
transplantation his urine contained CMV. He was
treated im for 10 days with 106 units of human
1 R. J. O'Reilly, L. K. Everson, G. Emodi, J. Hansen,
E. Smithwick, E. Grimes, S. Pahwa, D. Armstrong, B.
Dupont, and R. Good, "Effects of Exogenous Interferon
in Cytomegalovirus Infections Complicating Bone Mar-
row Transplantation," presented at the Symposium on
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leukocyte interferon daily. Results of urine culture
became only transiently negative for CMV. The
PHA response was suppressed, as it was in pa-
tient no. 3.
Patient no. 9, a 24-year-old white female with
acute myelogenous leukemia, had had a bone-
marrow transplantation. She excreted CMV in the
urine. She received a single injection of 5 X 106
units of human leukocyte interferon daily for 10
days. After treatment all urine samples tested
yielded negative results. The last test was per-
formed on day 92 with negative results.
Side effects. Human leukocyte interferon did
not produce immediate or delayed serious side
effects after im administration. Of the nine pa-
tients treated, two had local reactions, with red-
ness and minimal tenderness at the site of ad-
ministration. This local reaction lasted for about
12 hr. Fever reactions of 38 C-38.5 C were seen
in two patients 6-8 hr after administration, with a
short duration of 4-6 hr.
Discussion
Infection with CMV in humans is associated with
a long course of disease. Since congenital infec-
tion with CMV does not necessarily imply a bad
prognosis, the possibility of antiviral treatment
becomes important. Treatment is based on the
unproved hypothesis that postnatal replication of
CMV continues to damage the tissue of infants.
Although unproved, the assumption that continued
infection is damaging seems reasonable.
In acquired CMV infections in children and
adults, the interaction between CMV and lympho-
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cytes may be important in the pathogenesis of the
disease. In immunologically depressed patients,
viruses might replicate in lymphocytes or in tissue,
with autoreactive potential. In cases of immuno-
logical hyporesponsiveness induced by tumors,
chemical agents, or conditioning therapy for trans-
plantation [25], CMV might selectively replicate
in an unrestricted fashion, culminating in a pos-
sibly fatal infection. In bone-marrow transplant
recipients, the rather frequent graft-vs.-host dis-
ease is often accompanied by CMV infection. It
is very difficult to distinguish symptoms of CMV
infection from those of graft-vs.-host disease.
Graft-vs.-host disease may be mediated by viruses.
Hirsch et al. and De Maeyer et al. have described
in their mouse studies not only an antiviral but
also an anti-graft-vs.-host effect with a potent in-
terferon preparation [26, 27].
In our investigation human leukocyte interferon
had a long-lasting inhibitory effect on viral excre-
tion of three of nine patients. A similar observa-
tion has been made by Arvin et al. [28]. It is not
known whether the dosage used in this study was
adequate; better results might be obtained with a
larger dose or with twice daily administration of
interferon, because the t~ of interferon is < 24
hr [29]. On the other hand, the immune response
of the patients might be responsible for the results
of therapy with human leukocyte interferon that
were observed in treated patients. In addition,
studies have shown that congenitally infected in-
fants have a deficiency in production of circulat-
ing interferon [30].
The side effects observed during treatment with
human leukocyte interferon, including a small
local reaction at the injection site and fever, are
of minor importance. These side effects can in no'
way be compared with those of chemotherapeutic
agents such as fluorodeoxyuridine, iododeoxyuri-
dine, or cytosine arabinoside. Long-term therapy
with human leukocyte interferon may be possible
without any serious side effects.
The immunosuppressive effects of interferon are
well documented in vitro and in vivo (in animal
models). Interferon suppresses the functions of
T-cells, such as lymphocyte response to mitogens
[31]. Our findings suggest that human leukocyte
interferon may be useful in the treatment of CMV
infections and may completely or transiently in-
hibit and/or partially reduce viral excretion in the
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urine and in the leukocytes. More observation is
necessary to evaluate the usefulness of human leu-
kocyte interferon in treatment of patients infected
with CMV.
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